Drug maker Pfizer announcing positive results today from a late-stage trial of a gene therapy treatment for adults with certain cases of severe hemophilia A. The Phase 3 trial seeks to test the therapy to treat blood clotting disorder, and Pfizer shares are currently up 0.5%.